Clearmind Medicine Inc. has begun patient enrollment at Tel Aviv Sourasky Medical Center (TASMC), with the first participant dosed on the day of the announcement. The new site expands the company’s multinational Phase I/IIa study of CMND‑100, an oral, non‑hallucinogenic MEAI‑based neuroplastogen designed to reduce alcohol cravings in patients with Alcohol Use Disorder (AUD).
The trial’s first cohort has already reported a favorable safety profile, with no serious adverse events and high tolerability. An independent Data and Safety Monitoring Board (DSMB) has recommended that the study continue, a decision that underscores the robustness of the early safety data and supports the company’s confidence in the drug’s therapeutic potential.
By adding TASMC, Clearmind accelerates recruitment momentum across its global network, which now includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah‑University Medical Center. The expanded geographic reach is expected to shorten enrollment timelines and enhance the diversity of the study population, positioning the company to generate more comprehensive efficacy data in a shorter period. This milestone also signals to investors that the company is progressing toward the next phases of development, potentially shortening the path to regulatory approval and market entry in a $35 billion AUD treatment market.
CEO Dr. Adi Zuloff‑Shani emphasized the significance of the enrollment: “The recruitment of the first patient at TASMC is a significant step that further accelerates our global trial.” He added that the DSMB’s recommendation “reinforces our confidence in CMND‑100’s safety and therapeutic potential.”
The market has responded positively to the announcement, with analysts highlighting the safety data and DSMB recommendation as key drivers of the favorable reaction. The company’s continued progress in a high‑need therapeutic area reinforces its strategic positioning and supports expectations for future milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.